Can extracorporeal membrane oxygenation (ECMO) turn the tide and save lives in severe acute respiratory distress syndrome (ARDS)? The EOLIA trial investigated the use of ECMO in patients with severe ARDS. This multicenter, randomized trial compared ECMO to conventional mechanical ventilation strategies in ARDS patients who were not responding to standard treatments. The study found that ECMO did not significantly improve 60-day mortality compared to conventional management. However, ECMO was associated with a lower incidence of death due to refractory hypoxemia, and there was a trend toward improved long-term outcomes. The trial suggests that ECMO may be beneficial in specific subsets of ARDS patients, but it also highlights the need for further research to identify which patients are most likely to benefit from this intensive therapy.